ConductScience.org, home

Gene · 54600

UGT1A9: UDP glucuronosyltransferase family 1 member A9

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. UGT1A9: UDP glucuronosyltransferase family 1 member A9. Genes, record 54600. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/54600

On this page

Gene

Symbol
UGT1A9
HGNC
Name
UDP glucuronosyltransferase family 1 member A9
HGNC
NCBI Gene ID
54600
NCBI Gene
HGNC ID
HGNC:12541
HGNC
Ensembl
ENSG00000241119
NCBI Gene
Aliases
HLUGP4, LUGP4, UDPGT, UDPGT 1-9, UGT-1I, UGT1-09, UGT1-9, UGT1.9, UGT1A9S, UGT1AI, UGT1I
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O60656UDP-glucuronosyltransferase 1A95300Ensembl, GeneID, HGNC

Source UniProt

Patents38

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1469126O60656Espacenet
EP 4650780 A22025-11-197091O60656Espacenet
EP 4641201 A22025-10-296993O60656Espacenet
JP 2025529142 A2025-09-045167O60656Espacenet
US 12371689 B22025-07-295167O60656Espacenet
JP 2025517969 A2025-06-126993O60656Espacenet
JP 2025517970 A2025-06-127091O60656Espacenet
US 11891360 B22024-02-064O60656Espacenet
JP 2024500397 A2024-01-0924O60656Espacenet
KR 1020230124974 A2023-08-2812O60656Espacenet

1 to 10 of 38

See all 38 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants761

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleUGT1A9 papersNewest fiscal year
P30CA021765Cancer Center Support Grant (CCSG)112025
ZIABC005708Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers112025
P30ES005022Rutgers Center for Environmental Exposure and Disease (CEED)72025
ZIABC005562Xenobiotic receptors62025
R01CA080728Oncogenic Impact of eIF4E-dependent RNA Export in Cancer42025
R01CA098571Molecular Mechanisms of eIF4E Mediated Transformation42025
T32GM007019Clinical Therapeutics42025
ZIABC010627Clinical Pharmacogenetics42025
P30AI027763UCSF-Bay Area Center for AIDS Research32025
P30CA008748Cancer Center Support Grant32025

1 to 10 of 761Source NIH's project files

See all 761 nih grants

Papers2,066

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
SGPP1 as a tumor suppressor in esophageal squamous cell carcinoma: Potential molecular mechanisms involving UGT1A9/UGT2B28 and clinical prognostic significance.Oncol Rep202642788356PubTator, text miningPubMed
Orchestration of kaempferol nuclear translocation by phase ii metabolic enzymes and efflux transporters suppresses colorectal cancer.PLoS One202642743329PubTator, text miningPubMed
Physiologically based pharmacokinetic modeling of propofol: Impact of liver cirrhosis on systemic exposure and model-informed dose optimization according to Child-Pugh classification.Toxicol Appl Pharmacol202642641698PubTator, text miningPubMed
Association Between UGT1A9 rs13418420 Polymorphism and Propofol Induction Characteristics in Chinese Female Patients Undergoing Brief Gynecological Procedures.Pharmgenomics Pers Med202642634660PubTator, text miningPubMed
Impact of UGT1A9 Expression on Analgesic Efficacy and Safety of Postoperative Ketorolac in Thyroid Cancer Surgery: A Prospective Cohort Study.J Pain Res202642491921PubTator, text miningPubMed
Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Cipepofol Across Diverse Clinical Populations.Pharmaceutics202642357380PubTator, text miningPubMed
Fraxetin Inhibits UGT1A1 and UGT1A9 Activities In Vitro: Inhibition Kinetics, Molecular Dynamics Simulation, and Prediction of Herb-Drug Interaction Risk.Pharmaceuticals (Basel)202642356585PubTator, text miningPubMed
Utility of Relative Activity Factors to Determine Fraction Glucuronidation and Clearance of Icenticaftor in Humans.Pharm Res202642343021PubTator, text miningPubMed
Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions.Front Pharmacol202642272844PubTator, text miningPubMed
In vitro metabolism and inhibitory effect of vonifimod on drug-metabolizing enzymes in human liver preparations.Toxicol Res202642021864PubTator, text miningPubMed

1 to 10 of 2,066

See all 2,066 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/54600

GET https://conductscience.org/api/genes/v1/54600/patents?page=2